BiotechTube

Alglucosidase alfa GZ419829

Pre-clinicalActive
1 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glycogen Storage Disease Type II

Conditions

Glycogen Storage Disease Type II

Trial Timeline

Jun 10, 2021 → Oct 28, 2026

NCT ID
NCT04848779

About Alglucosidase alfa GZ419829

Alglucosidase alfa GZ419829 is a pre-clinical stage product being developed by Sanofi for Glycogen Storage Disease Type II. The current trial status is active. This product is registered under clinical trial identifier NCT04848779. Target conditions include Glycogen Storage Disease Type II.

What happened to similar drugs?

3 of 7 similar drugs in Glycogen Storage Disease Type II were approved

Approved (3) Terminated (0) Active (4)
✅ALGLUCOSIDASE ALFA (MYOZYME)SanofiApproved
✅Avalglucosidase alfa (GZ402666)SanofiApproved
✅Avalglucosidase alfaSanofiApproved
🔄avalglucosidase alfaSanofiPhase 3
🔄Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 3
🔄Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
🔄Oral prednisolone + Placebo for oral prednisoloneUltragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
3
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04848779Pre-clinicalActive

Competing Products

20 competing products in Glycogen Storage Disease Type II

See all competitors
ProductCompanyStageHype Score
mRNA-3745ModernaPhase 2
0
alglucosidase alfaSanofiPre-clinical
26
avalglucosidase alfaSanofiPhase 3
44
MyozymeSanofiPhase 2/3
38
MyozymeSanofiPre-clinical
26
Avalglucosidase AlfaSanofiPhase 2
35
MyozymeSanofiPhase 2/3
38
ALGLUCOSIDASE ALFA (MYOZYME)SanofiApproved
43
Avalglucosidase alfa (GZ402666)SanofiApproved
47
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 3
40
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 2
39
Alglucosidase alfaSanofiPhase 2
35
Avalglucosidase alfaSanofiApproved
50
MyozymeSanofiPhase 1/2
32
alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])SanofiPre-clinical
26
alglucosidase alfaSanofiPre-clinical
26
Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
44
BEAM-301: Single dose of BEAM-301 administered by IVBeam TherapeuticsPhase 1/2
33
Oral prednisolone + Placebo for oral prednisoloneUltragenyx PharmaceuticalPhase 3
34
UX053 + Antipyretic + H2 Blocker + H1 BlockerUltragenyx PharmaceuticalPhase 1/2
18